Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.56, Implies 599% Upside

Unicycive Therapeutics' average stock price target increased from $28.4 to $29.56 by 9 analysts, with a range of $13 to $42. This implies a 599% upside from the Oct. 6 closing price. The consensus rating remains 'Buy' with all 9 analysts recommending purchase.

Original reporting
Published Oct 7, 2026, 7:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 7:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.56, Implies 599% Upside — source image
Decision brief

The 30-second read

Low
01

Why it matters

The target raise signals modest bullish sentiment but provides little actionable insight given the company's micro‑cap status and lack of new operational news.

02

Market read

The article offers a minor analyst opinion update with limited trading relevance.

03

What to watch

No new fundamental data; the change reflects analyst sentiment rather than company performance.

Relevance 5/10Novelty 4/10Timing: today

Background

Analyst consensus price target for Unicycive Therapeutics, Inc. was raised from $28.4 to $29.56, implying a 599% upside based on the latest closing price.

Market effects

none

none

none

Counterpoint

Price target upgrades may be overly optimistic for a micro‑cap with limited liquidity.

Key entities

  • Unicycive Therapeutics, Inc.

    Biotech firm whose analyst price targets were updated.

Related articles

$UNCYMed

Unicycive Therapeutics Reports Q3 2026 Results, $59 Million in Cash and Securities

Unicycive Therapeutics reported a Q3 2026 net loss of $7.0 million, or $0.25 per share, with $59 million in cash. The FDA accepted its OLC NDA resubmission, setting a March 25, 2027 PDUFA date. The company expects its cash runway to extend beyond 2027, including potential OLC launch costs. Research and development expenses decreased to $2.2 million from $3.0 million a year earlier, while general and administrative expenses increased to $6.6 million from $4.4 million.

$UNCYMed

Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update - New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an assigned Prescription Drug User Fee Act (

MedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA

Unicycive Therapeutics announced the FDA accepted its resubmitted NDA for Oxylanthanum Carbonate (OLC), setting a PDUFA target action date of March 25, 2027. The resubmission addresses manufacturing deficiencies cited in a prior CRL. OLC is an investigational phosphate binder for CKD patients on dialysis, with potential market advantages due to its formulation.